Dr. Matthew C. Baker, MD
Rheumatology (Rheumatology Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 159
Licensed in California since 2014, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Harvard Medical School
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
CA license A129608 (first issued 2014; current) -
Internal Medicine Physician
CA license A129608 (first issued 2014; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 159
- Services billed
- 378
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 126 | 80 |
| Established patient office or other outpatient visit, 20-29 minutes | 61 | 46 |
| New patient office or other outpatient visit, 60-74 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Stanford, CA | 76 |
| Methotrexate (methotrexate sodium) Other prescribers in Stanford, CA | 71 |
| Rinvoq (upadacitinib) | 53 |
| Leflunomide Other prescribers in Stanford, CA | 45 |
| Azathioprine Other prescribers in Stanford, CA | 30 |
| Hydroxychloroquine Sulfate Other prescribers in Stanford, CA | 26 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Stanford, CA | 17 |
| Enbrel (etanercept) Other prescribers in Stanford, CA | 15 |
| Cevimeline Hcl | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 24 payments worth $25,981 in total to this clinician.
| Argenx US, Inc. | $10,150 |
|---|---|
| Neurocrine Biosciences, Inc. | $7,800 |
| Amgen Inc. | $6,632 |
| Eli Lilly and Company | $1,400 |
| Consulting Fee | $24,495 |
|---|---|
| Travel and Lodging | $894 |
| Food and Beverage | $593 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Argenx US, Inc. Sep 11, 2025 | Consulting Fee VYVGART · Immunology | $8,750 |
| Amgen Inc. Nov 11, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $3,648 |
| Neurocrine Biosciences, Inc. Mar 19, 2025 | Consulting Fee | $1,700 |
| Amgen Inc. May 6, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $1,672 |
| Eli Lilly and Company Jun 20, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,400 |
| Neurocrine Biosciences, Inc. May 21, 2025 | Consulting Fee | $1,400 |
| Neurocrine Biosciences, Inc. Dec 18, 2025 | Consulting Fee | $1,400 |
| Neurocrine Biosciences, Inc. Jul 24, 2025 | Consulting Fee | $1,100 |
| Amgen Inc. Dec 16, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $912 |
| Neurocrine Biosciences, Inc. Jul 9, 2025 | Consulting Fee | $900 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Neurocrine Biosciences, Inc. Dec 18, 2025 | Consulting Fee | $1,400 |
| Amgen Inc. Dec 16, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $912 |
| Amgen Inc. Nov 11, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $3,648 |
| Neurocrine Biosciences, Inc. Oct 28, 2025 | Consulting Fee | $600 |
| Argenx US, Inc. Sep 11, 2025 | Consulting Fee VYVGART · Immunology | $8,750 |
| Argenx US, Inc. Sep 6, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Dallas, TX | $384 |
| Argenx US, Inc. Sep 6, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Dallas, TX | $217 |
| Argenx US, Inc. Sep 6, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Dallas, TX | $126 |
| Argenx US, Inc. Sep 6, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Dallas, TX | $70.00 |
| Argenx US, Inc. Sep 5, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Dallas, TX | $97.85 |
| Neurocrine Biosciences, Inc. Sep 4, 2025 | Consulting Fee | $700 |
| Neurocrine Biosciences, Inc. Jul 24, 2025 | Consulting Fee | $1,100 |
| Neurocrine Biosciences, Inc. Jul 9, 2025 | Consulting Fee | $900 |
| Eli Lilly and Company Jun 20, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,400 |
| Neurocrine Biosciences, Inc. May 21, 2025 | Consulting Fee | $1,400 |
| Amgen Inc. May 6, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $1,672 |
| Argenx US, Inc. Apr 17, 2025 | Consulting Fee VYVGART HYTRULO · Neurology | $313 |
| Neurocrine Biosciences, Inc. Mar 19, 2025 | Consulting Fee | $1,700 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $425,109 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Argenx US, Inc. - P3 Inebilizumab in IgG4-Related Disease (Mitigate)
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.